{"id":"NCT03594123","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type","officialTitle":"A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-11","primaryCompletion":"2022-09-19","completion":"2022-09-19","firstPosted":"2018-07-20","resultsPosted":"2023-11-14","lastUpdate":"2023-11-14"},"enrollment":259,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":[]},{"type":"DRUG","name":"Brexpiprazole","otherNames":[]}],"arms":[{"label":"Prior Brexpiprazole","type":"EXPERIMENTAL"},{"label":"Prior Placebo","type":"EXPERIMENTAL"}],"summary":"Active treatment extension study of the 331-14-213 trial, to assess the long-term safety and tolerability of oral brexpiprazole as treatment in adult participants with agitation associated with dementia of the Alzheimer's type (AAD).","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) by Severity","timeFrame":"From first dose through 30 days after last dose of study drug (Up to approximately Week 16)","effectByArm":[{"arm":"Prior Brexpiprazole","deltaMin":20.9,"sd":null},{"arm":"Prior Placebo","deltaMin":13.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["40681915","39534972"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":163},"commonTop":["Nasopharyngitis"]}}